Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

These 2 Markers May Impact MGUS Progression to MM

Leuk Lymphoma; ePub 2018 Jan 18; Vallet, et al

Publish date:: January 24, 2018

2 bone turnover markers appear to play a role in the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM), researchers concluded after conducting a cross-sectional follow-up study involving 241 individuals. Investigators assessed how the bone formation marker propeptide of type I collagen (PINP) and the bone resorption marker β-CrossLaps (CTX) impacted disease progression from MGUS to MM. Among the results:

PINP and CTX levels were significantly higher in patients with MM, vs those with MGUS.
Patients who progressed to MM had increasing concentrations of PINP and CTX.
These levels remained unchanged in patients with stable MGUS.

Citation:

Vallet S, Hoyle N, Kyle R, Podar K, Pecherstorfer M. A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. [Published online ahead of print January 18, 2018]. Leuk Lymphoma. doi:10.1080/10428194.2017.1421757.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Leukemia, Myelodysplasia, Transplantation

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

New cancer drugs may have saved more than 1.2 million Americans,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,